SCHEMBL27423745

SCHEMBL27423745

C[C@H]1O[C@@H](n2cnc3c(OCc4ccc(OC(F)F)cc4)nc(Cl)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 6/20 0.54
▸ NT5E P21589 3/20 0.47
▸ PDE2A O00408 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ SLC29A1 Q99808 1/20 0.42
▸ MAPK1 P28482 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ GMNN O75496 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27424490 0.86 SLC29A1 (0.57) ADORA3SLC29A1
SCHEMBL27423891 0.84 NT5E (0.50) ADORA3NT5EPDE2ALMNATP53
SCHEMBL27428645 0.84 ADORA3 (0.56) ADORA3NT5EPDE2ALMNATP53
SCHEMBL27430559 0.79 ADORA3 (0.49) ADORA3SLC29A1
SCHEMBL27423523 0.77 SLC29A1 (0.60) ADORA3NT5ELMNATP53SLC29A1
SCHEMBL27428742 0.77 SLC29A1 (0.56) ADORA3SLC29A1
SCHEMBL27425390 0.76 SLC29A1 (0.62) ADORA3SLC29A1
SCHEMBL27425126 0.75 SLC29A1 (0.59) ADORA3SLC29A1
SCHEMBL27428046 0.75 ADORA3 (0.52) ADORA3SLC29A1
SCHEMBL27427947 0.75 SLC29A1 (0.61) ADORA3SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134541-A1 HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS iTeos Belgium SA (BE) 2024-06-27 — — WO disclosed
Send feedback